Bacillus pumilus strains to improve animal performance parameters

By using novel Bacillus pumilus strains DSM 34299 and DSM 34300 as animal feed additives, the problems of pathogen inhibition and animal health improvement in the prior art have been solved, realizing an alternative to antibiotics and vaccinations, and improving animal growth performance and health.

CN121443722APending Publication Date: 2026-01-30CHR HANSEN AS
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202480044128.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-29
Filing Date
2024-08-28
Publication Date
2026-01-30

AI Technical Summary

Technical Problem

There is a lack of probiotic strains in the current technology that can effectively inhibit pathogens and improve animal health and performance, especially as antibiotic use is phased out, and traditional antibiotic treatment and vaccination are costly and have limited effectiveness.

Method used

Two novel Bacillus pumilus strains, DSM 34299 and DSM 34300, and their variants, were used as animal feed additives. These strains were sensitive to antibiotics and exhibited inhibitory activity against pathogens such as Escherichia coli, Staphylococcus aureus, and Clostridium perfringens, improving the health and growth performance of monogastric and ruminant animals.

Benefits of technology

It significantly inhibits related pathogens, reduces disease outbreaks, and improves animal growth performance, including increased body weight, daily weight gain, milk production, and milk quality. It provides an alternative to antibiotics and vaccinations and reduces the cost of traditional treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121443722A_ABST
    Figure CN121443722A_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to compositions comprising Bacillus pumilus having a positive impact on animal performance parameters, the use of Bacillus pumilus for preventing, reducing or controlling bacterial colonization or infection, a method of improving one or more animal performance parameters, and a kit. In particular, the present disclosure relates to Bacillus pumilus DSM 34300 and DSM 34299.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure generally relates to compositions comprising Bacillus pumilus that have a positive effect on animal performance parameters, the use of Bacillus pumilus for the prevention, reduction, or control of bacterial colonization or infection, a method for improving one or more animal performance parameters, and a kit. In particular, this disclosure relates to Bacillus pumilus strains DSM 34300 and DSM34299. Background Technology

[0002] Ingestion of pathogens (especially bacterial pathogens, but also including viruses and other pathogenic microorganisms) is a common problem in most livestock animals. Pathogens are known to cause disease in animals, leading to several detrimental effects, including weight loss, diarrhea, abdominal cramps, and kidney failure. For immunosuppressed or malnourished animals, the effect of diarrhea alone can be fatal. Therefore, animal health is of paramount importance, and any disease can potentially affect animal health and performance, thereby impacting operational productivity and profitability. This is especially true for production animals where final body weight and carcass weight are of high economic importance at slaughter.

[0003] Pathogens frequently spread between animals, and animal-to-animal transmission is often unavoidable. The most common solution to this problem is to administer antibiotics, but in addition to being costly, this solution can lead to the development of antibiotic-resistant bacterial strains. Therefore, there is a general consensus in the field that the overuse of antibiotics should be avoided. This phase-out of antibiotics has increased the demand for cost-effective feed additives that effectively support the health of livestock herds.

[0004] The use of Bacillus-based probiotics in the diets of livestock has yielded beneficial health and productivity effects. More particularly, strains of Bacillus species have gained greater importance in the feed industry due to the heat stability of their spores and their ability to survive the pelleting process of animal feed.

[0005] The European Union's phase-out of antibiotic growth promoters in 2006 increased the demand for cost-effective feed additives that are highly effective and have low susceptibility to inhibitors of human and veterinary importance.

[0006] Probiotic feed additives based on the genus Bacillus are known to have positive effects on the health and production of livestock. These products are relevant to the feed industry because the spores are heat-stable and can survive pelleting processes at temperatures up to 90°C-95°C. The bacteria that form endospores are Bacillus subtilis (…). Bacillus subtilis ) and Bacillus licheniformis ( Bacillus licheniformisIt is generally considered safe (GRAS) by the U.S. Food and Drug Administration (FDA) and approved by the American Association of Feed Control Officials (AAFCO) for acceptance in animal diets or water.

[0007] WO 2015 / 091770 describes a marine-derived Bacillus pumilus strain and its use in weaning feed for pigs. A rifampicin-resistant strain isolated from seaweed is specifically mentioned. No overall therapeutic effect was observed, and no positive impact on the average diarrhea score in piglets was obtained.

[0008] WO 2016 / 060935 describes compositions comprising one or more bacteria for improving the in vitro true digestibility and / or neutral detergent fiber digestibility of animal feed. Various Bacillus strains are mentioned, namely Bacillus pumilus, Bacillus amyloliquefaciens, etc. Bacillus amyloliquefaciens Bacillus subtilis and Bacillus licheniformis were among the strains identified. Bacillus pumilus strains were described as exhibiting enzymatic activity against casein and / or xylan under aerobic conditions. The effects of different preserved strains on the in vitro true digestibility and / or neutral detergent fiber digestibility of animal feed were investigated; however, the species of the preserved strains were not mentioned, and therefore, Bacillus pumilus was not described in any way as a particularly preferred strain or associated with any beneficial effects.

[0009] WO 2019 / 002476 describes an isolated strain of Bacillus pumilus (DSM 32539) that exhibits the ability to survive in a simulated gastric passage environment and demonstrates growth in the presence of 0.3% chicken bile at pH 6. Compared to the baseline strain, the isolated strain showed significantly increased xylanase activity. This strain also exhibited inhibition against various pathogens. No significant differences were observed in mean daily gain, feed conversion ratio, feed intake, and diarrhea score compared to the positive control group.

[0010] WO 94 / 11492 describes the use of Bacillus pumilus and Bacillus coagulans in direct feeding microorganisms for use in poultry feed. Bacillus coagulans (and its mixtures). No significant improvement in mortality or overall weight gain was observed in the trials conducted.

[0011] Therefore, there is still a need for probiotic strains that can be used to improve the health and performance of production animals.

[0012] The inventors of this disclosure have conducted extensive screening and research to address the objective of providing probiotic strains that can be used to improve the health and performance of production animals, and have identified two novel Bacillus pumilus strains that have shown effective pathogen inhibition and have been demonstrated to improve the health and performance of production animals from both monogastric and ruminant sources. Summary of the Invention

[0013] This disclosure provides a Bacillus pumilus strain selected from the group consisting of: a) a strain preserved as DSM 34299, b) a strain preserved as DSM 34300, and c) a variant strain of DSM 34299 or DSM 34300, which is obtained by using the preserved strain as starting material and retains or further improves the properties of DSM 34299 or DSM 34300.

[0014] The disclosed *Bacillus pumilus* strain is sensitive to ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline, and chloramphenicol; and is also resistant to *Escherichia coli* (…). E. coli Staphylococcus aureus ( Staphylococcus carnosus ) and Clostridium perfringens ( Clostridium perfringens It has inhibitory activity 。

[0015] A bacterial strain is a bacterium that remains genetically unchanged during growth or reproduction. When referring to a strain, multiple such identical bacteria are included.

[0016] The strains disclosed herein and compositions containing these strains have proven effects on the health and growth performance of both monogastric and ruminant animals.

[0017] Compositions containing the novel probiotic strains disclosed herein can be fed to animals, for example, as direct feed microorganisms (DFM), as animal feed additives, in premix form, or directly incorporated into animal feed.

[0018] At least one strain of Bacillus pumilus according to this disclosure can be added to feed by the supplier during production, after production, or by the person feeding the animal immediately before feeding it. The Bacillus pumilus bacteria used in the methods and compositions described herein are particularly suitable because they are able to survive (as spores) under the thermal and pressure conditions of the process for producing dried pelleted feed products.

[0019] The study described in the examples aimed to investigate the effects of DSM 34299 and DSM 34300 on pathogen growth and animal performance parameters.

[0020] By demonstrating in vitro pathogen inhibition and in vivo animal performance improvements, this disclosure describes and demonstrates the beneficial effects of Bacillus pumilus strains DSM 34299 and DSM 34300 on improving the health of animals that have been administered these strains.

[0021] Clostridium diseases are caused by bacteria belonging to a group of organisms called Clostridium. These bacteria are important in farm animal production because they can cause significant disease problems. The Clostridium group of organisms produces very potent exotoxins (poisons) that can harm animals.

[0022] Necrotic enteritis (NE) caused by Clostridium perfringens has become a serious economic problem in modern poultry production. Some of the in vivo studies described in the examples aimed to investigate the effects of feed additives containing Bacillus subtilis strains according to this disclosure on the pathogenesis of NE in broiler cage studies. Other in vivo studies in poultry focused on performance in the presence or absence of Clostridium perfringens challenge.

[0023] Enterotoxemia is a leading cause of mortality in calves. It primarily affects beef cattle breeds, and losses due to enterotoxemia can account for up to 20% of total mortality. Clostridium perfringens type A is considered the primary causative agent.

[0024] Typical treatment for calves with mild clinical signs consists primarily of antibiotics (especially penicillin) and the use of Clostridium perfringens antitoxin products. Several injectable antitoxin preparations containing specific antibodies against the toxins produced by Clostridium perfringens are currently available; however, no effective treatment is currently available. Clostridium difficile infection prevention currently relies mainly on vaccination; however, such vaccination has been reported to be only partially effective in prevention. Vaccination of the entire herd should be carried out according to the recommendations on the vaccine label. This is a costly procedure and cannot achieve complete prevention.

[0025] The purpose of the in vitro studies described in the examples is to investigate the ability of several Bacillus pumilus strains to inhibit relevant pathogens, these strains being susceptible to relevant antibiotics and possessing other characteristics relevant to the use of Bacillus pumilus strains as animal feed or feed additives. Another purpose of the in vivo studies described in the examples is to investigate the subsequent effects of compositions comprising the identified Bacillus pumilus strains according to this disclosure on the growth and health performance of monogastric and ruminant animals.

[0026] This disclosure describes the beneficial effects of two novel Bacillus pumilus probiotic strains in inhibiting relevant animal pathogens and improving animal growth and health parameters. These beneficial effects have been evaluated in the following assays: (i) an in vitro assay demonstrating the inhibitory effect of the novel combination of probiotic strains on the growth of Escherichia coli and Staphylococcus aureus (Example 1); and (ii) an in vivo study demonstrating the efficacy of Bacillus pumilus in controlling experimentally induced subclinical necrotizing enterocolitis in broilers under floor-fence conditions (Example 2); and (iii) an in vivo study in small ruminants (sheep and lambs) demonstrating the effects of dietary supplementation with Bacillus pumilus on body weight gain, milk yield, and milk quality (Example 3).

[0027] These results demonstrate that the above-described composition containing novel Bacillus pumilus strains improves the health and performance of producing animals in both monogastric and ruminant livestock populations, thus providing a cost-effective and easy-to-apply alternative to traditional methods of treating and minimizing pathogen infections and diseases in livestock populations using antibiotics and vaccinations, while improving the growth performance of the receiving animals.

[0028] definition Generally, the terms and phrases used herein have their generally accepted meanings in the art, which can be discovered by referring to standard texts, journal articles, and context known to those skilled in the art. The following definitions are provided to clarify their specific use in the context of this disclosure.

[0029] As used in this article, the singular forms “a / an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0030] As used herein, the term “and / or” is intended to mean both combined (“and”) and exclusive (“or”) use, i.e., “A and / or B” is intended to mean “A alone, or B alone, or A and B together”.

[0031] Animal feed: The term "animal feed" refers to any compound, preparation, or mixture suitable for or intended for consumption by animals. Animal feed for monogastric animals contains concentrates as well as, for example, vitamins, minerals, enzymes, amino acids, and / or other feed ingredients (as in premixes). Animal feed may further contain forage and / or silage as a fiber source. Examples of poultry and ruminant feeds are given in the examples.

[0032] Composition: The term "composition" refers to a composition comprising a carrier and at least one bacterial strain as described herein. The compositions described herein may be direct feed microorganisms (DFM), animal feed additives or premixes, or animal feed.

[0033] Concentrates: The term “concentrate” refers to feeds with high protein and energy concentrations, such as fishmeal, molasses, oligosaccharides, sorghum, seeds and grains (e.g., whole or prepared from corn, oats, rye, barley, wheat, crushing, milling, etc.), oilseed filter cake (e.g., from cottonseed, safflower, sunflower, soybean (e.g., soybean meal), rapeseed / canola, peanut or peanut kernel), palm kernel cake, yeast-derived materials and distillers' grains (e.g., wet distillers' grains (WDS) and dry distillers' grains with solubles (DDGS)).

[0034] Control or prevention of Clostridium perfringens infection and / or necrotizing enteritis: The term "control or prevention of Clostridium perfringens infection and / or necrotizing enteritis" means a method and / or composition that partially or completely inhibits Clostridium perfringens infection and / or necrotizing enteritis in animals. Therefore, the term "control or prevention of Clostridium perfringens infection and / or necrotizing enteritis" means a reduction or complete elimination of Clostridium perfringens infection and / or necrotizing enteritis.

[0035] Direct feeding microorganisms: The term "direct feeding microorganisms" or "DFM" refers to live microorganisms, including spores, that, when applied in appropriate amounts, produce beneficial effects on the host, such as improved digestion or health.

[0036] Effective Amount / Effective Concentration / Effective Dosage: The terms "effective amount," "effective concentration," or "effective dose" are defined as the amount, concentration, or dose of one or more bacterial strains sufficient to improve digestion or yield in an animal. The absolute number of the actual effective dose depends on factors including the health condition of the animal in question and the presence of other components. The "effective amount," "effective concentration," or "effective dose" of a bacterial strain can be determined by routine measurements known to those skilled in the art. Examples of effective amounts for poultry and ruminants are given in the examples.

[0037] Feeding animals: The terms “feeding animals” or “administered to animals” mean the oral administration of the composition disclosed herein to animals in an effective amount. This oral administration may be repeated, for example, once or more daily for a specified period of time (such as days, weeks, weeks, months, or months). Feeding of poultry can be carried out, for example, as described in Example 2. Feeding of ruminants can be carried out, for example, as described in Example 3. Therefore, the terms “feeding” or “administered” mean any type of oral administration, such as via animal feed or via drinking water, or in some cases, via oral gavage or aerosol spray.

[0038] Inhibitory activity against Clostridium perfringens: The term "inhibitory activity against Clostridium perfringens" means that the growth of Clostridium perfringens is inhibited and / or some or all of the Clostridium perfringens are killed. This can be determined by the assay described in Example 1.

[0039] Inhibitory activity against Escherichia coli: The term "inhibitory activity against Escherichia coli" means that the growth of Escherichia coli is inhibited and / or some or all of the Escherichia coli are killed. This can be determined by the assay described in Example 1.

[0040] Inhibitory activity against Staphylococcus aureus: The term "inhibitory activity against Staphylococcus aureus" refers to Staphylococcus aureus (… Staphylococcus carnosus The growth of ) is inhibited and / or some or all of the Staphylococcus aureus are killed. This can be determined by the assay described in Example 1.

[0041] Isolated: The term “isolated” means that the bacterial strain described herein is in a form or environment that does not exist in nature, that is, the strain is isolated at least in part from one or more or all naturally occurring components associated with it in nature.

[0042] Antibiotic susceptibility: The term "antibiotic susceptibility" refers to the phenotypic property of a bacterial strain, namely, that the growth of the bacterial strain is inhibited under conditions under which the strain would otherwise grow. In this context, antibiotic susceptibility was tested according to CLSI guidelines (M07-A8 and M45-A2). A *Bacillus* strain is considered sensitive if growth is detected only at or below the breakpoint concentrations specified in EFSA Journal 2012; 10(6):2740 for vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline, and chloramphenicol. Regarding ampicillin, EFSA does not provide breakpoints for *Bacillus*; a breakpoint of 4 mg / L has been selected for a strain to be considered sensitive.

[0043] Stable: The term “stable” is a term known in the art, and in a preferred aspect, stable is intended to mean the ability of a microorganism to maintain its viable form until it is applied to an animal to improve the animal’s health.

[0044] Weight gain: An animal's weight gain is the increase in its body weight over a specified period. One parameter to view is the average weight gain or the daily weight gain. You can also view the animal's final average weight (as in Example 2) or the average daily weight gain (ADG) and final weight (as in Example 3). Attached Figure Description

[0045] Figure 1 The effect of feeding ewes with the composition of this disclosure containing a strain of Bacillus pumilus on the birth weight of lambs is shown.

[0046] Figure 2 This illustrates the interaction between feeding ewes with compositions containing Bacillus pumilus strains of this disclosure and the change in postnatal lamb weight over time.

[0047] Figure 3 The effect of feeding ewes with the composition disclosed herein containing a strain of Bacillus pumilus on the average daily weight gain (ADG) of lambs is shown.

[0048] Figure 4 The interaction between feeding ewes with the composition of this disclosure containing a strain of Bacillus pumilus and corrected milk production is shown.

[0049] Figure 5 The interaction between feeding ewes with the composition of this disclosure containing a strain of Bacillus pumilus and milk fat production is illustrated.

[0050] Figure 6 The interaction between feeding ewes with the composition of this disclosure containing a strain of Bacillus pumilus and milk protein production is illustrated. Detailed Implementation

[0051] Necrotizing enteritis Necrotic enteritis caused by Clostridium perfringens has become a serious economic problem in modern poultry production. This issue is a major concern for the poultry industry because it leads to production losses, increased mortality, reduced poultry welfare, and an increased risk of contamination in poultry products intended for human consumption. There is a general consensus that while clinical outbreaks of necrotic enteritis can lead to high levels of mortality, the subclinical form of the disease is more important than the clinical form because it can persist in broiler flocks without obvious clinical manifestations. Subclinical necrosis causes the greatest economic losses in poultry production because the disease remains undetected and untreated. Therefore, there remains a need for animal feed or feed additives that can prevent or minimize the development and impact of necrotic enteritis.

[0052] Susceptibility factors for necrotic enteritis have been identified as nutrition, flock stress response, the presence of pathogenic Clostridium perfringens strains in poultry, and coccidiosis. The latter (i.e., mucosal damage caused by coccidia pathogens) is the most well-known susceptibility factor for necrotic enteritis. In Example 2, the effect of the composition disclosed herein containing Bacillus pumilus strains was investigated, and a significant reduction in lesion scores was observed.

[0053] Some of the in vivo studies described in the examples aimed to investigate the effects of compositions of this disclosure containing strains of Bacillus pumilus according to this disclosure on the pathogenesis of necrotizing enterocolitis (NE) in broiler cage studies. Other in vivo studies in poultry focused on performance in the presence or absence of Clostridium perfringens and Eimeria oocysts.

[0054] Due to concerns about the spread of antimicrobial resistance, growth-promoting antibiotics have been banned in animal feed in many parts of the world, and consequently, the use of antimicrobial growth promoters is decreasing worldwide. Therefore, when selecting Bacillus pumilus strains for use in animal feed or as feed additives, it is important that the selected strains be susceptible to antibiotics. In vitro screening for antibiotic susceptibility of Bacillus pumilus strains is shown in Example 1.

[0055] Animal performance parameters This disclosure provides a method for improving one or more animal performance parameters selected from the group consisting of: i) increased body weight (BW), ii) increased birth weight, iii) increased average daily gain (ADG), iv) decreased coccidiosis lesion score, v) decreased Eimeria tenella lesion score, vi) decreased overall mortality, vii) increased milk yield, viiii) increased milk fat content, and ix) increased milk protein content by feeding animals with strains or compositions according to this disclosure.

[0056] On the other hand, this disclosure relates to the use of at least one strain of Bacillus pumilus disclosed herein or animal feed, animal feed additives or premixes containing at least one strain of Bacillus pumilus disclosed herein for improving the performance of animals, particularly monogastric animals or ruminants.

[0057] As demonstrated in the examples, administration of the disclosed Bacillus pumilus strains improved gastrointestinal health in animals (e.g., prevention or control of lesion scores) and provided improved animal performance parameters in treated animals compared to controls. These animal performance parameters include, but are not limited to, average daily gain (ADG), body weight (BW), reduced mortality, and improved milk yield and quality (increased milk fat and protein content).

[0058] Therefore, this disclosure relates to the use of strains or compositions according to this disclosure for improving one or more performance parameters of animals selected from the group consisting of: i) Weight gain (BW) ii) Increased birth weight, iii) Increased average daily weight gain (ADG). iv) Decreased coccidiosis lesion score, v) Decreased Eimeria coccidia lesion score. vi) Reduced overall mortality rate, vii) Increased milk production viii) Increased milk fat content, and ix) Increased milk protein content.

[0059] In one embodiment of this disclosure, "animal performance" is determined by the animal's weight gain and / or average daily weight gain. "Improved animal performance" means an increased weight gain and / or average daily weight gain due to the use of the animal feed, animal feed additive, or premix disclosed herein, compared to an animal feed that does not contain the animal feed, animal feed additive, or premix. Preferably, "improved animal performance" means an increased weight gain and / or average daily weight gain.

[0060] "Increased weight gain" refers to the increased body weight of an animal fed a diet containing the feed composition compared to an animal fed a diet not containing the feed composition disclosed herein. Specifically, animal weight gain (WG) is the increase in an animal's body weight over a specified period. In one embodiment, the improvement in weight gain is at least 0.5%, for example, at least 1%, for example, at least 2%, for example, at least 2.5%, for example, at least 3%, for example, at least 4%, for example, at least 5%, for example, at least 6%, for example, at least 7%, for example, at least 8%, for example, at least 9%, for example, at least 10%.

[0061] In one embodiment, the improvement in weight gain results in a weight gain of at least 0.5%, such as at least 0.8%, such as at least 1.2%, such as at least 1.5%, such as at least 1.8%, such as at least 2.0%, such as at least 2.5%, such as at least 3.0%, such as at least 4.0%, such as at least 5.0%, such as at least 6.0%, such as at least 7.0%. In a preferred embodiment, the improvement in weight gain results in a weight gain selected from the group consisting of: 1.8% to 2.0%, 2.0% to 2.2%, 2.2% to 2.4%, 2.4% to 2.6%, 2.6% to 2.8%, 2.8% to 3.0%, 3.0% to 3.2%, 3.2% to 3.4%, 3.4% to 3.6%, 3.6% to 3.8%, 3.8% to 4.0%, 4% to 5%, 5% to 7%, 7% to 10%, or any combination thereof.

[0062] In another embodiment, "animal performance" is determined by a reduction in overall mortality rate. "Reduction in overall mortality rate" means a reduction of at least 0.5%, for example, at least 1%, for example, at least 2%, for example, at least 2.5%, for example, at least 3%, for example, at least 4%, for example, at least 5%, for example, at least 6%, for example, at least 7%, for example, at least 8%, for example, at least 9%, for example, at least 10%.

[0063] In another embodiment, "animal performance" is determined by a reduction in the score for coccidiosis and / or Eimeria tenella lesions. "A reduction in the score for coccidiosis and / or Eimeria tenella lesions" means a reduction of at least 0.5%, for example, at least 1%, for example, at least 2%, for example, at least 2.5%, for example, at least 3%, for example, at least 4%, for example, at least 5%, for example, at least 6%, for example, at least 7%, for example, at least 8%, for example, at least 9%, for example, at least 10%.

[0064] In another embodiment, "animal performance" is determined by an increase in milk production. An "increase in milk production" means an increase of at least 0.5%, for example, at least 1%, for example, at least 2%, for example, at least 2.5%, for example, at least 3%, for example, at least 4%, for example, at least 5%, for example, at least 6%, for example, at least 7%, for example, at least 8%, for example, at least 9%, for example, at least 10%.

[0065] In another embodiment, "animal performance" is determined by an increase in milk fat content and / or milk protein content. "Increase in milk fat content and / or milk protein content" means an increase of at least 0.5%, for example, at least 1%, for example, at least 2%, for example, at least 2.5%, for example, at least 3%, for example, at least 4%, for example, at least 5%, for example, at least 6%, for example, at least 7%, for example, at least 8%, for example, at least 9%, for example, at least 10%.

[0066] In another embodiment, this disclosure relates to a method for improving performance parameters of one or more animals selected from the group consisting of: i) Weight gain (BW) ii) Increased birth weight, iii) Increased average daily weight gain (ADG). iv) Decreased coccidiosis lesion score, v) Decreased Eimeria coccidia lesion score. vi) Reduced overall mortality rate, vii) Increased milk production viii) Increased milk fat content, and ix) Increased milk protein content.

[0067] The method includes feeding animals with strains or compositions according to this disclosure.

[0068] Probiotic bacterial strains The probiotic strains disclosed herein are isolated, i.e., exist in forms or environments not found in nature, and exhibit surprising effects when used in compositions as described herein. The probiotic strain disclosed herein is *Bacillus pumilus*.

[0069] When selecting Bacillus pumilus strains for use in animal feed or animal feed additives (including as direct-feed microorganisms (DFM) or premixes), several evaluation-relevant characteristics exist, as these will affect the strain's performance and adaptability as a probiotic for animals. These characteristics include the strain's ability to grow on bile agar, its cellulase activity, its biofilm-forming ability, its protease activity, and its protein and fiber degradation capabilities. Finally, evaluating the ability of Bacillus pumilus strains to grow at different temperatures is highly relevant, and for probiotics intended for use in monogastric and ruminant animals, the relevant temperatures for testing growth are 37°C (the relevant body temperature of most monogastric and ruminant animals) and 41°C (the relevant body temperature of poultry).

[0070] These characteristics can be evaluated as described in Example 1.

[0071] In one embodiment of this disclosure, the composition comprising one or more probiotic strains is used to provide a total of 1 x 10 8 Up to 1 x 10 11 Between CFU / animal / day, for example, in 1 x 10 8 Up to 1 x 10 10 Between CFU / animal / day, for example, in 1 x 10 9 Up to 1 x 10 10 Between CFU / animal / day, for example, in 5 x 10 9 Up to 5 x 10 10 The dosage between CFU / animal / day is administered to the animal.

[0072] In a preferred embodiment of this disclosure, the composition comprising one or more probiotic strains is used to provide a total of 2 x 10 9 Up to 8 x 10 9 CFU / animal / day, e.g., 2.5 x 10 9 CFU / animal / day, e.g., 3 x 10 9 CFU / animal / day, e.g., 4 x 10 9 CFU / animal / day, e.g., 5 x 10 9 CFU / animal / day, e.g., 6 x 10 9 CFU / animal / day, e.g., 7 x 10 9 CFU / animal / day, e.g., 8 x 109 The animal was given a dose of CFU / animal / day.

[0073] The term "CFU / animal / day" refers to the amount of one or more probiotic strains administered to each animal per day. Therefore, this term excludes carriers (e.g., calcium carbonate), anti-caking agents (e.g., aluminum silicate and diatomaceous earth), and other components that may optionally be present in the composition.

[0074] The compositions disclosed herein comprise at least one species of the probiotic strain disclosed herein and at least one carrier and / or other components that make the compositions suitable for feeding animals or as an additive to drinking water.

[0075] In one embodiment of this disclosure, the composition comprises more than one probiotic strain, with Bacillus pumilus strain comprising at least half of the CFU / g of the composition.

[0076] In another embodiment of this disclosure, the composition comprises more than one probiotic strain, with Bacillus pumilus strains comprising less than half of the CFU / g of the composition.

[0077] In another embodiment of this disclosure, the composition comprises more than one probiotic strain, and the composition may comprise more than one Bacillus pumilus strain present in equal or unequal portions.

[0078] In one embodiment of this disclosure, the Bacillus pumilus strain present in the composition is a strain preserved as DSM34300.

[0079] In one embodiment of this disclosure, the Bacillus pumilus strain present in the composition is a strain deposited as DSM34299.

[0080] In one embodiment of this disclosure, the composition comprises Bacillus pumilus deposited as DSM 34300 or Bacillus pumilus deposited as DSM 34299.

[0081] In one embodiment of this disclosure, the composition comprises two different probiotic strains, namely Bacillus pumilus deposited as DSM34300 and Bacillus pumilus deposited as DSM 34299, optionally in a ratio of 1:1 in terms of colony forming units (CFU).

[0082] In one embodiment of this disclosure, the composition comprises two distinct probiotic strains: Bacillus pumilus deposited as DSM 34300 and Bacillus pumilus deposited as DSM 34299, optionally in a 1:1 ratio of colony-forming units (CFU). In such embodiments, the composition does not contain any other microbial components, but may contain other components, such as one or more carriers and / or one or more feed ingredients.

[0083] The probiotic strains of the compositions disclosed herein may be provided in the form of spores and / or bacterial cells. In one embodiment of this disclosure, Bacillus strains are provided in the form of spores.

[0084] In one embodiment of this disclosure, the composition comprises a certain amount of Bacillus pumilus strain DSM34300 or DSM 34299 to provide a concentration of 1 x 10⁻⁶. 8 With 1 x 10 11 The short-lived Bacillus strain DSM34300 or DSM 34299, with a CFU / day between [value missing], is preferably provided in 1 x 10 [value missing] CFU / day. 9 With 1 x 10 10 Bacillus pumilus strains DSM34300 or DSM 34299, with a CFU / day ratio. In a preferred embodiment, the composition disclosed herein comprises a certain amount of Bacillus pumilus strains DSM 34300 or DSM 34299 to provide 3 x 10 9 The CFU / day of Bacillus subtilis strains DSM 34300 or DSM34299.

[0085] In one embodiment of this disclosure, the microbial component of the composition consists of a certain amount of probiotic strains to provide 1 x 10 9 CFU / day of Bacillus pumilus preserved in DSM 34300 or 3 x 10 9 CFU / day of Bacillus pumilus preserved under DSM34299. In such embodiments, the composition does not contain any other microbial components, but may contain other components, such as one or more carriers and / or one or more feed ingredients.

[0086] In one embodiment of this disclosure, the composition is present in animal feed or animal feed additives, and in this embodiment may contain a certain amount of Bacillus pumilus strain DSM 34300 or DSM 34299 to provide a 1 x 10 6 With 1 x 10 9 Between CFU / g feed, for example, at 1 x 10 6 With 5 x 106 Short-lived Bacillus strains DSM 34300 or DSM 34299 with CFU / g feed.

[0087] Composition application form and formulation The probiotic strains present in the compositions disclosed herein are provided in commercially relevant forms known to those skilled in the art. Therefore, in the embodiments, the probiotic strains of the composition are present in a dried (e.g., spray-dried or freeze-dried) or frozen form. Different probiotic strains present in the compositions disclosed herein may be present in different forms in the mixture, for example, some may be spray-dried and some may be freeze-dried. The composition may be provided in any suitable form, such as in a liquid (e.g., gel, slurry, etc.) or in a solid (e.g., powder or pellet) form.

[0088] For compositions in premix form, the probiotic strains disclosed herein can be added to a carrier to prepare a mineral-vitamin mixture (premix), which can then be added to animal feed at the desired inclusion rate.

[0089] Alternatively, for compositions in the form of animal feed, the probiotic strains disclosed herein can be formulated together with animal feed ingredients, as shown below. Such combinations of the disclosed compositions and animal feed ingredients may optionally be in the form of pellets extruded by a standard pelleting process.

[0090] This disclosure also provides a method for producing animal feed, animal feed additives or premixes, the method comprising adding the probiotic strains disclosed herein to the animal feed or related components thereof.

[0091] In one embodiment, this disclosure provides an animal feed, animal feed additive, or premix that contains the probiotic strain disclosed herein and further contains one or more concentrates, vitamins, minerals, enzymes, amino acids, and / or other feed ingredients.

[0092] In one embodiment, the animal feed, animal feed additive, or premix comprises the composition disclosed herein (the composition comprises Bacillus pumilus deposited as DSM 34300 and optionally Bacillus pumilus deposited as DSM 34299), and further comprises one or more concentrates, vitamins, minerals, enzymes, amino acids, and / or other feed ingredients.

[0093] In one embodiment, the animal feed, animal feed additive, or premix comprises the composition disclosed herein (the composition comprises Bacillus pumilus deposited as DSM 34299 and optionally Bacillus pumilus deposited as DSM 34300), and further comprises one or more concentrates, vitamins, minerals, enzymes, amino acids, and / or other feed ingredients.

[0094] In one embodiment, the animal feed, animal feed additive, or premix comprises the composition disclosed herein (the composition comprises Bacillus pumilus deposited as DSM 34300 and Bacillus pumilus deposited as DSM 34299), and further comprises one or more concentrates, vitamins, minerals, enzymes, amino acids, and / or other feed ingredients.

[0095] In a preferred embodiment, the animal feed, animal feed additive, or premix comprises the composition disclosed herein (composed of Bacillus pumilus deposited as DSM 34300 and / or Bacillus pumilus deposited as DSM 34299), and further comprises one or more concentrates, vitamins, minerals, enzymes, amino acids, and / or other feed ingredients.

[0096] In a specific embodiment, the animal feed is a total mixed ration (TMR) comprising 0% to 80% forage sources (e.g., hay, silage, or forage). Typically, forage includes the edible parts of plants (in addition to isolated grains) that can provide feed for the animals or can be harvested for animal feeding. As an example, a TMR may comprise 0% to 80% corn; and / or 0% to 80% sorghum; and / or 0% to 70% wheat; and / or 0% to 70% barley; and / or 0% to 30% oats; and / or 0% to 40% soybean meal.

[0097] In one embodiment, the composition disclosed herein containing probiotic strains is mixed with forage, concentrates, and optionally other feed components to obtain TMR.

[0098] In another embodiment, the composition of this disclosure containing probiotic strains is mixed with concentrates, vitamins, and / or minerals to obtain a premix. This premix can be mixed with a final diet to obtain a TMR. In another embodiment, the TMR and the composition of this disclosure containing probiotic strains are mixed with one or more enzymes. In another embodiment, the composition of this disclosure containing probiotic strains is mixed with one or more other feed ingredients, such as colorants, stabilizers, growth-improving additives and flavor compounds / flavorings, saturated or polyunsaturated fatty acids (PUFAs), essential oils, antioxidants, antimicrobial peptides, antifungal peptides, and amino acids.

[0099] In a particular embodiment, the animal feed component consists of or contains milk (e.g., from dairy cows, goats, or sheep), for example, for feeding calves. In another particular embodiment, the animal feed component consists of or contains milk substitutes, for example, for feeding calves. In one embodiment, the composition of this disclosure containing probiotic strains is mixed with water, milk, or a milk replacer for feeding calves, piglets, or other weaned animals.

[0100] In another embodiment, the animal feed component may contain one or more vitamins, such as one or more fat-soluble vitamins and / or one or more water-soluble vitamins. In another embodiment, the animal feed component may optionally contain one or more minerals, such as one or more trace minerals and / or one or more macro minerals. Typically, fat-soluble vitamins and water-soluble vitamins, along with trace minerals, form part of a so-called premix intended to be added to the feed, while macro minerals are typically added separately to the feed. Non-limiting examples of fat-soluble vitamins include vitamin A, vitamin D3, vitamin E, and vitamin K, such as vitamin K3. Non-limiting examples of water-soluble vitamins include vitamin B12, biotin and choline, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid, and pantothenate, such as Ca-D-pantothenate. Non-limiting examples of trace minerals include boron, cobalt, chloride, chromium, copper, fluoride, iodine, iron, manganese, molybdenum, selenium, and zinc. Non-limiting examples of macro minerals include calcium, magnesium, potassium, and sodium.

[0101] The animal feeds, animal feed additives, or premixes disclosed herein may also contain at least one enzyme selected from the group consisting of: phytase (EC 3.1.3.8 or 3.1.3.26); xylanase (EC 3.2.1.8); galactanase (EC 3.2.1.89); α-galactosidase (EC 3.2.1.22); protease (EC 3.4); phospholipase A1 (EC 3.1.1.32); phospholipase A2 (EC 3.1.1.4); lysophospholipase (EC 3.1.1.5); phospholipase C (3.1.4.3); phospholipase D (EC 3.1.4.4); amylase, such as α-amylase (EC 3.2.1.1); lysozyme (EC 3.2.1.17); cellulase (EC 3.2.1.4); and β-glucanase (EC 3.1.1.17). 3.2.1.6), or any mixture thereof.

[0102] The animal feeds, animal feed additives, or premixes disclosed herein may further contain one or more added amino acids. Examples of amino acids used in animal feeds are rumen-protected or non-rumen-protected lysine, alanine, β-alanine, threonine, methionine, and tryptophan. The animal feeds, animal feed additives, or premixes disclosed herein may further contain colorants, stabilizers, growth-improving additives, and flavor compounds / flavorings, polyunsaturated fatty acids (PUFAs), essential oils, antioxidants, antimicrobial peptides, and antifungal peptides. Examples of colorants are carotenoids, such as β-carotene, astaxanthin, and lutein. Examples of flavor compounds / flavorings are methoxycresol, anethole, decadecyl, undecyl, and / or dodecadecyl lactones, ionone, irisone, gingerol, piperidine, propylidene phthalide, butylidene phthalide, capsaicin, and tannins. Examples of saturated fatty acids are C16 and C18, such as palmitic acid and oleic acid, while polyunsaturated fatty acids are C18, C20, and C22 polyunsaturated fatty acids, such as linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, and γ-linolenic acid. Examples of reactive oxygen species (ROS) generators are chemicals such as perborates, persulfates, or percarbonates; and enzymes such as oxidases, oxygenases, or synthases.

[0103] In one embodiment, the animal feed, animal feed additive, or premix contains one or more anticoccidial agents.

[0104] In one embodiment, the animal feed, animal feed additive, or premix further comprises a carrier. The carrier may comprise one or more of the following compounds: water, glycerol, ethylene glycol, 1,2-propanediol or 1,3-propanediol, sodium chloride, sodium benzoate, potassium sorbate, sodium sulfate, potassium sulfate, magnesium sulfate, sodium thiosulfate, calcium carbonate, sodium citrate, dextrin, maltodextrin, glucose, sucrose, sorbitol, lactose, whey, whey permeate, wheat flour, wheat bran, corn gluten meal, starch, and cellulose.

[0105] In embodiments, the animal feed, animal feed additive, or premix further comprises one or more additional microorganisms. In specific embodiments, the animal feed, animal feed additive, or premix further comprises bacteria from one or more of the following genera: *Lactobacillus*, *Lactococcus*, *Lactobacillus spp.*, *Streptococcus*, *Bacillus*, *Pediococcus*, *Enterococcus*, *Leuconostoc*, *Carnivora*, *Propionibacterium*, *Bifidobacterium*, *Clostridium*, *Wesmania* (…). Weizmania (and the genus *Macrococcus* or any combination thereof.)

[0106] In a particular embodiment, the animal feed, animal feed additive, or premix further comprises bacteria from one or more of the following strains: Bacillus amyloliquefaciens, Bacillus subtilis, Bacillus pumilus, Bacillus polymyxa, Bacillus licheniformis, Bacillus paralicheniformis, Bacillus megaterium, Bacillus coagulans, Bacillus circulans, Bacillus simplex, and Bacillus mojaveniformis. Bacillus mojavensis ), Bacillus safortiformis ( Bacillus safensis ), Bacillus simplex, Bacillus atrophus ( Bacillus atrophaeus ), Methyltrophic Bacillus ( Bacillus methylotrophicus ), Bacillus sicca ( Bacillus siamensis ), Bacillus cereus ( Bacillus vallismortis ), Bacillus tekiria ( Bacillus tequilensis (or any combination thereof).

[0107] In a particular embodiment, the animal feed, animal feed additive, or premix further comprises one or more types of yeast. The one or more types of yeast may be selected from the group consisting of: Saccharidae (…). Saccharomycetaceae yeasts ( ) Saccharomyces (such as brewer's yeast) S. cerevisiae ) and / or Bula yeast ( S. boulardii Kluyveromyces ( )), Kluyveromyces ( Kluyveromyces (such as Max Kluyveromycin) K. marxianus ) and Kluyveromycin ( K. lactis ), Candida genus (such as Candida utilis ( )), Candida genus ( C. utilis ), also known as the genus *Saccharomyces* ( Torula Yeasts), Pichia genus (such as Pichia pastoris ( P. pastoris ), and the genus *Cytosaccharomyces* (such as *Dalkai* cytosaccharomyces* (…). T. delbrueckii ), Phaefoetida ( Phaffia ) and Basidiomycetes ( Basidiomycota ).

[0108] The compositions disclosed herein may additionally comprise cryoprotectants, lyophilization protectants, antioxidants, nutrients, fillers, flavorings, or mixtures thereof. The compositions may be in freeze-dried or lyophilized form. Preferably, the compositions comprise one or more of cryoprotectants, lyophilization protectants, antioxidants, and / or nutrients; more preferably, they comprise cryoprotectants, lyophilization protectants, and / or antioxidants; and most preferably, they comprise either a cryoprotectant or a lyophilization protectant, or both. The uses of protectants such as cryoprotectants and lyophilization protectants are known to those skilled in the art. Suitable cryoprotectants or lyophilization protectants include monosaccharides, disaccharides, trisaccharides, and polysaccharides (e.g., glucose, mannose, xylose, lactose, sucrose, trehalose, raffinose, maltodextrin, starch, and gum arabic), polyols (e.g., erythritol, glycerol, inositol, mannitol, sorbitol, threitol, xylitol), amino acids (e.g., proline, glutamic acid), complex substances (e.g., skim milk, peptone, gelatin, yeast extract), and inorganic compounds (e.g., sodium tripolyphosphate). Suitable antioxidants include ascorbic acid, citric acid and its salts, gallate, cysteine, sorbitol, mannitol, and maltose. Suitable nutrients include sugars, amino acids, fatty acids, minerals, trace elements, and vitamins (e.g., B vitamins, vitamin C). The composition may optionally contain additional substances, including fillers (e.g., lactose, maltodextrin), and / or flavoring agents.

[0109] Animal diets can be formulated as, for example, powdered (non-pelletized) or pelleted feed. Typically, the milled feed is mixed and supplemented with adequate amounts of essential vitamins and minerals according to the instructions for the type discussed. Bacterial cultures and optionally enzymes can be added as solid or liquid formulations. For example, for powdered feed, solid or liquid culture formulations can be added before or during the ingredient mixing step. For pelleted feed, the (liquid or solid) composition of this disclosure containing probiotic strains can be added to the pelleted food after the pelleting step. Typically, the liquid composition of this disclosure contains probiotic strains, optionally accompanied by polyols (e.g., glycerol, ethylene glycol, or propylene glycol), and is added after the pelleting step, for example, by spraying the liquid formulation onto pellets.

[0110] Another aspect of this disclosure relates to a method for feeding animals, the method comprising administering to the animal (e.g., a monogastric animal or a ruminant) a composition comprising a strain of probiotics of this disclosure. In one embodiment of this disclosure, the monogastric animal being fed is poultry. The term "poultry" refers to domesticated birds raised by humans, referring to the eggs they produce and / or their meat and / or their feathers. Poultry includes breeding birds, broilers, and laying hens. Poultry includes members of the superorder Galliformes (birds), particularly the order Galliformes (which includes chickens, guinea fowl, quails, and turkeys) and the family Anatidae within the order Anatidae, which is often referred to as "waterfowl" and includes domestic ducks and geese. Poultry also includes other birds killed for their meat, such as pigeons and ostriches. Examples of poultry include chickens (including laying hens, broilers, and chicks), ducks, geese, pigeons, turkeys, and quails.

[0111] In one embodiment of this disclosure, the animal being fed is a ruminant. Ruminants include dairy cows, cattle, sheep, deer, and goats.

[0112] Ruminants have digestive systems that are fundamentally different from those of monogastric animals, and therefore it cannot be concluded that compositions designed for monogastric animals and proven effective in monogastric animals will also be suitable for and effective in ruminants. Therefore, providing compositions that are effective in both monogastric and ruminant animals is not straightforward.

[0113] An animal's digestive system is involved in the mechanical and chemical digestion of food, the absorption of nutrients, and the elimination of indigestible materials from the body. The main difference between a monogastric digestive system and a ruminant digestive system is that digestion in a monogastric system primarily occurs in the stomach, while digestion in a ruminant system is foregut fermentation. A monogastric digestive system consists of a single stomach, while a ruminant digestive system consists of four stomachs (reticulum, rumen, omasum, and abomasum). Monogastric digestion is primarily found in omnivores and carnivores, while ruminants are herbivores.

[0114] A monogastric digestive system is an organ system that helps digest both animal and plant materials. This digestive system is called monogastric because it consists of a single stomach. Humans, horses, pigs, poultry, dogs, birds, and rabbits have monogastric digestive systems. Digestion begins when feed enters the mouth. Both chemical and mechanical digestion begin in the mouth. Saliva contains enzymes to digest carbohydrates. The esophagus is the passageway that carries feed to the stomach. Various enzymes are secreted into the stomach cavity to digest proteins in the feed. Animals with monogastric digestive systems primarily feed on animal tissues. Their diet is easily digestible; therefore, a single stomach is sufficient for this purpose. The small intestine primarily absorbs nutrients from digested feed. The large intestine absorbs water from poorly digestible materials.

[0115] The ruminant digestive system refers to the organ system in which the digestion of plant material occurs. Cows, cattle, sheep, deer, and goats are examples of animals with a ruminant digestive system. Ruminants lack teeth in the front of their upper jaw; instead, they have a hard pad of skin called the dentate pad. In addition to the basic anatomy of the animal digestive system, the ruminant digestive system consists of four stomachs: the rumen, reticulum, omasum, and abomasum. The first three stomachs (rumen, reticulum, and omasum) are involved in the breakdown of plant fibers and the digestion of non-fibrous compounds. The microbiome is involved in this process. The microbiome breaks down cellulose and starch, for example, through fermentation, producing volatile fatty acids such as acetic acid, butyric acid, and propionic acid. These volatile fatty acids are used as an energy source by ruminants. Digestive enzymes are secreted in the fourth stomach, called the abomasum. Therefore, in ruminants, fermentation occurs before the digestion of feed. This process is therefore called foregut fermentation. Furthermore, ruminants chew these partially digested or regurgitated foods by returning them from the first stomach. The small and large intestines of ruminants resemble a monogastric digestive system. However, ruminants contain a large cecum for further digestion of fiber.

[0116] In one embodiment of this disclosure, the composition disclosed herein is used in a method for preventing and / or minimizing respiratory diseases in ruminants.

[0117] In another embodiment of this disclosure, the composition disclosed is used in a method for preventing and / or minimizing respiratory diseases in monogastric animals.

[0118] As demonstrated in the examples, administration of the composition of this disclosure containing the probiotic strains described herein improved animal performance in animals receiving the composition compared to controls, including increased body weight (BW), increased birth weight, increased average daily gain (ADG), reduced coccidiosis lesion score, reduced Eimeria coccidiosis lesion score, reduced overall mortality, increased milk yield, increased milk fat content, and increased milk protein content.

[0119] In the context of this disclosure, “variants thereof” should be understood as Bacillus pumilus that has alterations in the wild-type nucleotides of the genome of an organism (e.g., Bacillus pumilus DSM 34300) that result in a change in the phenotype of the organism, wherein such alterations may be deletions, substitutions, insertions, and / or modifications of one or more nucleotides. In the context of this disclosure, deletion should be understood as a gene mutation resulting in the removal of one or two nucleotides from the wild-type nucleotide sequence of an organism's genome; insertion should be understood as the addition of one or more nucleotides to the wild-type nucleotide sequence; substitution (or point mutation) should be understood as a gene mutation in which a nucleotide in the wild-type nucleotide sequence is altered by another nucleotide; frameshift should be understood as a gene mutation resulting from the insertion or deletion of a certain number of nucleotides not divisible by three in the wild-type nucleotide sequence, thereby altering the reading frame and resulting in a translation completely different from the original reading frame; the introduction of a stop codon should be understood as a point mutation in the DNA sequence that results in a premature stop codon; and inhibition of substrate binding encoding a protein should be understood as any mutation in the nucleotide sequence that causes a change in the protein sequence that prevents the substrate from binding to its protein catalytic site. Furthermore, knockout mutants should be understood as gene mutations resulting in the removal or deletion of a gene (such as an entire gene or an entire open reading frame) from the genome of an organism.

[0120] Algorithms for aligning sequences and determining the degree of sequence identity between them are well known in the art. For the purposes of this disclosure and as an example, one such algorithm is based on aligning two sequences using blastp, available from the National Center for Biotechnology Information (NCBI) at https: / / blast.ncbi.nlm.nih.gov, applying standard parameter settings (matrix: BLOSUM62, gap penalty: presence: 11 extension: 1, conditional composition score matrix adjustment), and subsequently quantifying identical amino acid pairs at the same positions in the aligned amino acid sequences. A similar process can be performed to align nucleotide sequences, in this case using blastn, available from the NCBI at https: / / blast.ncbi.nlm.nih.gov, applying standard parameters.

[0121] In one embodiment, this disclosure relates to a variant of Bacillus pumilus DSM 34300, wherein the average nucleotide identity (ANI) of the Bacillus pumilus variant has at least 99%, such as at least 99.5%, such as at least 99.8%, such as at least 99.9%, similar to the genome of the strain deposited at the German Center for Microbiology and Cell Culture under accession number DSM 34300.

[0122] In one embodiment, this disclosure relates to a variant of Bacillus pumilus DSM 34299, wherein the average nucleotide identity (ANI) of the Bacillus pumilus variant has at least 99%, such as at least 99.5%, such as at least 99.8%, such as at least 99.9%, similar to the genome of the strain deposited at the German Center for Microbiology and Cell Culture under accession number DSM 34299.

[0123] The illustrative examples presented below are intended to better describe this disclosure. However, the described formulations relate only to some means of some embodiments of this disclosure and should not be considered as limiting its scope.

[0124] Example Experiments have been conducted to evaluate the beneficial effects of the disclosed Bacillus pumilus strains in both monogastric and ruminant animals under both in vitro and in vivo conditions.

[0125] Example 1 In vitro tests were conducted to study antibiotic resistance and inhibitory effects on selected pathogens, as well as to investigate other performance characteristics of probiotics intended for use in animal feed.

[0126] Material: Veal broth (VIB) (Difco, 234420) Veal broth (VIB) agar (VIB + 1.5% bacteriological agar (agar number 1), Oxoid LP0011) Cation-regulated Muller Hinton Broth 2 (Fluka) T3 agar plates (per liter: 3 g tryptone, 2 g tryptose, 1.5 g yeast extract, 0.05 M sodium dihydrogen phosphate, 0.005 g MnCl2 [pH 6.8], and 15 g agar) Laura-Bertani (LB) broth (g / L: Bactotryptone 10 (Difco 0123), Yeast extract 5 (Oxoid L21), NaCl 10 (Merck No. 106404)) Brain-Heart Infusion (BHI) Agar (Oxoid CM375) Bile salts (bile extract, porcine; Sigma-Aldrich B8631) Bioassay petri dish (Nunc 240845) Petri dish (Procudan 140096, a petri dish with ribs) Physiological saline solution containing peptone (0.9% sodium chloride, 1% peptone) FKP ISO-SENSITEST broth (Oxoid CM0473) Microtiter Plate (MTP) NUNC, Denmark Omni tray / single-hole plate N 242811 Thermo Scientific / NUNC Denmark Deep-well microtitering 96-well tray (DW) without RNase / DNase (ThermoFisher Science) Ampicillin (Sigma-Aldrich, A9518-5G) Vancomycin (Sigma-Aldrich, V1764-250MG) Gentamicin (Sigma-Aldrich, G1264-50MG) Kanamycin (Sigma-Aldrich, K1377-1G) Streptomycin (Sigma-Aldrich, S6501-5G) Erythromycin (Sigma-Aldrich, E-5389) Clindamycin (Sigma-Aldrich, C2569-10MG) Tetracycline (Sigma-Aldrich, T-7660) Chloramphenicol (Sigma-Aldrich, C0378-5G) Escherichia coli ( Escherichia coli O101 H-, K99 F5 (National Serum Institute, Copenhagen, Denmark) Escherichia coli O147:K89 F4 H19 (National Serum Institute, Copenhagen, Denmark) Escherichia coli O149:k91,k88a,c,h10 NCTC10650 (National Center for Type Culture Collection, UK) Escherichia coli ATCC11775 (American Center for Type Culture Collection) Escherichia coli Cp6salp3 (Copenhagen Veterinary University) Clostridium perfringens type A, DSM756, Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen [Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures] Clostridium perfringens type C, NCTC3180, National Collection of Type Cultures (UK) Clostridium perfringens CCUG2036 (Culture Collection of the University of Gothenburg, Sweden) Clostridium perfringens CCUG2037 (Culture Collection of the University of Gothenburg, Sweden) Clostridium perfringens CCUG44727 (Culture Collection of the University of Gothenburg, Sweden) Staphylococcus aureus DSM20501, Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen [Leibniz Institute DSMZ - German Center for the Preservation of Microorganisms and Cell Cultures] All the above pathogen strains were maintained at -80°C in LB in BHI containing 20% ​​glycerol.

[0127] Bacillus cultures: One hundred and one hundred and one strains of Bacillus pumilus isolated from various sources (e.g., feces, soil, food sources) and collected from strain collection centers were maintained at -80°C in VIB containing 20% ​​glycerol on an MTP motherboard.

[0128] Aerobic isolates of bacterial spore formation were identified by 16S ribosomal sequence and gyrB (Wang et al., 2007), as described below, according to “Guidance on the assessment of bacterial susceptibility to inhibitors of human and veterinary importance.” EFSA Journal 2012;10(6):2740. Antibiotic susceptibility was screened, and bile resistance and sensitivity to low pH, enzyme activity, growth in different culture media, thermostability, and spore formation were assessed as described in WO 2013 / 153159.

[0129] Antibiotic susceptibility as measured by MIC Antibiotic susceptibility of Bacillus pumilus strains was analyzed by measuring the minimum inhibitory concentration (MIC) of many antibiotics. The method used was the broth microdilution method as outlined in the CLSI standards (Clinical and Laboratory Standards Institute M07-A8 and M45-A2).

[0130] The suspension of the overnight culture of the test strain was prepared at approximately 10... 5 Inoculate at a concentration of CFU / ml (colony-forming units / ml) into ISO-SENSITEST broth (Oxoid CM0473) in microtiter plates containing two serial dilutions of the test antibiotic (total volume 100 µl / well) and incubate aerobically at 37°C for 20–24 hours. After 20 hours of incubation, record the result as the lowest concentration of antibiotic that inhibits visible growth. This test was performed twice as two independent biological replicates.

[0131] Screening for Bacillus strains to inhibit pathogenic Escherichia coli and Staphylococcus aureus Pure colonies of Escherichia coli and Staphylococcus aureus (grown on TSA+SB agar at 37°C) were suspended in sterile PepSalDiluent to obtain 0.5 McFarland, corresponding to approximately 1 × 10⁻⁶. 8 CFU / ml.

[0132] Standard inoculum (Escherichia coli and Staphylococcus aureus; 2, 5, and 10 µL) was added to LB agar (35 ml). The inoculated agar was poured into single-well plates and fitted with 96-pin caps. The agar was allowed to cure for 20–30 min. The 96-pin caps were removed, and the wells were dried in a laminar flow hood for 30–60 min. Three copies of Bacillus subtilis (5 µL of overnight culture grown at 37°C in BHI-broth with shaking at 150 rpm) were added to the wells. These plates were incubated at 30°C for 48 h. Each assay was performed in duplicate.

[0133] Approximate concentrations of Escherichia coli and Staphylococcus aureus on agar plates 2 µL of 0.5 McFarland / 35 ml agar: (1 x 10 8 CFU / ml) / (35ml / 0.002ml) = 6 x10 3 CFU / ml 5 µL of 0.5 McFarland / 35 ml agar: (1 x 10 8 CFU / ml) / (35ml / 0.005ml) = 1.5 x10 4 CFU / ml 10 µL of 0.5 McFarland / 35 ml agar: (1 x 10 8 CFU / ml) / (35ml / 0.01ml) = 3 x10 4 CFU / ml The radius of the clear inhibition zone around the Bacillus was measured and recorded as “3=high” - more than 2 mm, “2=medium” - between 0.5 and 2 mm, and “1=low” - less than 0.5 mm, and 0=no inhibition.

[0134] All data is repeated on separate dates.

[0135] Clostridium perfringens inhibition by agar spot test Pour VIB agar into bioassay dishes (200 ml per dish) and dry thoroughly in a sterile workbench. Spot overnight Bacillus pumilus cultures (2 µl each) onto the surface of the VIB agar dishes and incubate overnight at 37°C. Allow Clostridium perfringens strains to grow anaerobically on BHI agar overnight at 37°C. Add 2 ml of the overnight Clostridium perfringens culture to 200 ml of liquid BHI agar, mix, and gently cover the bioassay dishes with Bacillus pumilus spots. Incubate these dishes anaerobically at 37°C for 1 day.

[0136] The radius of the clear inhibition zone around the Bacillus was measured and recorded as “3=high” - more than 2 mm, “2=medium” - between 0.5 and 2 mm, and “1=low” - less than 0.5 mm, and 0=no inhibition.

[0137] All data is repeated on separate dates.

[0138] Other health parameters When selecting Bacillus pumilus strains for use in animal feed or animal feed additives (including as direct-feed microorganisms (DFM) or premixes), several evaluation-relevant characteristics exist, as these will affect the strain's performance and adaptability as a probiotic for animals. These characteristics include the strain's ability to grow in the presence of bile, its cellulase activity, its biofilm-forming ability, and its ability to degrade fiber, starch, protein, and feed components. Finally, evaluating the ability of Bacillus pumilus strains to grow at different temperatures is highly relevant, and for probiotics intended for use in monogastric and ruminant animals, the relevant temperatures for testing growth are 37°C (the relevant body temperature of most monogastric and ruminant animals) and 41°C (the relevant body temperature of poultry).

[0139] result The results of the different tests are summarized in Tables 1-3 below.

[0140] Table 1 Results of susceptibility of selected Bacillus pumilus strains to selected antibiotics Table 2 Results, performance, and adaptability of the selected Bacillus pumilus strains Table 3 Results of the selected Bacillus pumilus strains, their inhibition against Escherichia coli and Staphylococcus aureus, and their growth capacity at different temperatures. As can be seen from Tables 1-3 above, not all Bacillus pumilus strains possess the same capabilities. Only Bacillus pumilus strains #3 (exhibited as DSM 34299) and #5 (exhibited as DSM 34300) contain all the necessary capabilities of probiotic strains intended for use in animal feed or animal feed additives. These two strains are susceptible to antibiotics, readily form biofilms, and can degrade proteins and fibers. Furthermore, they are highly effective in inhibiting Escherichia coli and Staphylococcus aureus, and can grow at both 37°C and 41°C, making them suitable for ruminants and monogastric animals (including poultry). Other Bacillus pumilus strains tested failed in one or more of these parameters, rendering them less useful or useless as a probiotic component in animal feed or animal feed additives.

[0141] Example 2 In vivo studies in monogastric animals (poultry) – efficacy of Bacillus pumilus in controlling experimentally induced subclinical necrotizing enteritis in broilers under ground-fence conditions.

[0142] Overview Despite advancements in nutrition, stable management, and genetics, necrotic enteritis (NE) remains one of the most challenging diseases in poultry production. Acute or clinical NE can lead to high mortality rates in poultry, while subclinical NE results in reduced growth due to poor health. Of these two severity levels, the subclinical form is the most common compared to the acute or clinical form.

[0143] Since the banning of antimicrobial growth promoters, which were successfully used to control nocturnal emission (NE), there has been a continuous search for alternative methods for prevention and / or treatment. The use of microorganisms and microbial-derived products can provide the preventative immunity needed in chicken production management. Microorganisms produce a large number of molecules with antimicrobial properties, and they can also have beneficial effects through interactions with their hosts.

[0144] Therefore, the aim of this study was to evaluate the preventive potential of different Bacillus pumilus strains against experimentally induced necrotizing enteritis (NE) in broilers. The efficacy of the treatments was assessed by individual intestinal lesion scores, supplemented by surveys of mortality and body weight (BW). Three distinct treatment groups were included: an infected, untreated control (IUC) group and two treatment groups receiving different Bacillus pumilus strains.

[0145] Materials and Methods Experimental induction of necrotic enteritis (NE) depends on a combination of several predisposing factors prior to inoculation with a virulent Clostridium perfringens strain. In the current study, all animals were exposed to a high-protein growth diet containing 30% fishmeal from day 17 until the end of the study. High-protein growth diets are standard in poultry production, but they are also considered a predisposing factor that increases the risk of necrotizing enteritis development in herds.

[0146] All poultry were challenged on days 14 and 16 by oral gavage with an overdose of coccidiosis inoculum (Paracox-8).

[0147] An overview of the composition of the inoculum can be found in Table 4.

[0148] Table 4: Number of oocysts / mL of inoculum The aim of this study was to evaluate the preventive properties of two different strains of Bacillus pumilus against subclinical necrotizing enteritis in broilers. Finally, approximately 10 mg of the strain was administered orally to all groups on days 18, 19, 20, and 21. 9 CFU (clostridium perfringens) is used to induce necrotizing enteritis in birds. This strain is NetB positive and produces alpha toxin.

[0149] First, in this specific experimental setting, the administration of probiotics did not cause any adverse events in the broilers. Throughout the study, there were no cases of coccidiosis or treatment-related mortality, and all animals exhibited normal clinical behavior.

[0150] The induction of subclinical NE was successful, as 72.6% of birds in the IUC showed lesions caused by NE and 1.9% of NE-related mortality was recorded.

[0151] result The inclusion of the test product was measured by Chr. Hansen. In the IUC group, the level of sporogenous strains present was as expected, at 6 x 10⁻⁶. 3 -7 x 10 3CFU / g feed. Both treatment groups (DSM 34300 and DSM 34299) achieved the expected coverage rate of 1 x 10⁻⁶ CFU / g feed. 6 - 4 x 10 6 CFU / g feed. No significant deviations were observed in the Bacillus count.

[0152] mortality rate The study revealed that the overall mortality rate was higher than normal, even though it was not considered to be related to the challenge.

[0153] A significant difference in overall mortality was observed in DSM 34300 from day 1 to day 27: 1.9% compared to 8.7% in the untreated control group with infection.

[0154] A non-significant difference was observed for DSM 34299, but a numerical difference was observed: 4.9% compared to 8.7% in the untreated control group with infection.

[0155] It is worth noting that any reduction in mortality rate (even if not significant) is beneficial to producers.

[0156] Table 5: Overview of overall mortality percentage and NE-related mortality during the study period Results of coccidiosis The coccidiosis lesion score was studied as ordinal data using a cumulative linked model (procedure CLM for package ordinal). Treatment duration and number of days were added as fixed effects. All groups were compared to T01. Post-hoc pairwise comparisons were performed without adjustment. Groups with different letters (e.g., a and b) were significantly different (P < 0.05).

[0157] The coccidiosis lesion score results showed that the mean total coccidiosis lesion score in the untreated control group (IUC) was 1.36, which was significantly higher than that in the two treatment groups.

[0158] The same pattern was observed in the Eimeria coccidia lesion score measurement, and this result was expected because the two measurements are correlated.

[0159] Table 6a: Total coccidiosis lesion score on day 22 + D23 Table 6b: Eimeria coccidia lesion scores on days 22 and 23 The body weight of the different groups was monitored on day 22 of the study and is presented in Table 7 below. This revealed that the group receiving DSM34299 experienced an unexpected weight gain of 8.4%. Such a large difference in body weight is rare in poultry production.

[0160] Differences in body weight at D22 were investigated using a linear mixed regression model, where columns were considered random effects and treatments were considered fixed effects. All treatments were compared to the IUC. The least squares mean and its standard error are also shown in the table below. 95% confidence intervals (CIs) for differences from T01 were estimated. Post-hoc pairwise comparisons were performed without adjustment. Groups with different letters (e.g., a and b) were significantly different (P < 0.05).

[0161] Table 7: Weight The aim of this study was to evaluate the preventive properties of two strains of Bacillus pumilus against subclinical necrotizing enteritis in broilers. As part of the experimental model, poultry were inoculated with a moderate number of coccidia oocysts (composed of two species, Eimeria tenella and Eimeria gigantea) starting from day 20 of the study, while being provided with a low-quality growing feed with a high fishmeal protein content (30% fishmeal).

[0162] First, in this specific experimental setting, administration of probiotics did not induce any adverse events in broilers. Throughout the study, there were no coccidiosis or treatment-related deaths, and all animals exhibited normal clinical behavior. The results indicated that Bacillus pumilus strain DSM 34300 significantly reduced mortality, while Bacillus pumilus strain DSM 34299 provided a numerical reduction in mortality, although this reduction was not significant. Both tested Bacillus pumilus strains showed significant reductions in coccidiosis lesion scores and Eimeria tenella lesion scores. Both tested Bacillus pumilus strains also increased the body weight of animals receiving the composition disclosed herein containing either of the Bacillus pumilus strains.

[0163] Example 3 In vivo studies in small ruminants (sheep) - the effect of dietary supplementation with Bacillus pumilus on weight gain The experimental study was conducted on a dairy sheep farm in Sicily and lasted for a total of 120 days. One hundred pregnant ewes of homogeneous gestation status (assessed by ultrasound and examined by specialists) were selected from a large flock on the same farm. Approximately 45 days before parturition, the ewes were randomly assigned to two treatments: a control group fed a standard diet (CON), while the treatment group received the same diet supplemented with Bacillus pumilus present as DSM 34299 (BP). All animals had free access to water and were allowed to roam in both indoor and outdoor enclosures throughout the study.

[0164] During gestation, ewes were fed 2 kg hay / sheep / day (divided into two meals) and 300 g / sheep of concentrate in a single meal each day. During lactation, ewes received 500 g / sheep of concentrate and 2 kg hay / sheep / day in two meals. The composition of the gestation and lactation concentrates is shown in Table 8. The probiotic product was thoroughly mixed with the concentrate immediately before feeding the sheep each day.

[0165] Newborn lambs were weighed on the same day. They were then weighed every other week (14 days apart) until weaning. At 45 days of age, the lambs were weaned, and the ewes were milked twice daily. For the first 30 days, milk production was recorded weekly for each sheep, and individual milk samples were collected for milk composition analysis using Milkoscan and Bactoscan (Foss Analytics, Hamburg, Germany).

[0166] Table 8. Composition of the experimental concentrate. result When ewes were administered Bacillus pumilus (DSM 34299) during pregnancy (BP), the birth weight of lambs was significantly higher than that of lambs born to ewes that were not given probiotics (CON). This was observed in... Figure 1 middle.

[0167] From farrowing to weaning, i.e., from day 0 to day 45, the weight of the lambs was tracked and recorded. Four different measurements were taken, with each measurement approximately one week apart. The weighing results are available on [website / document / etc.]. Figure 2 The study showed a significant difference in lamb weight between ewes fed gestation and lactation concentrates and control lambs. Lambs in the BP group gained significantly more weight than those in the CON group. Figure 2 It can be seen that the weight of BP lambs was higher at all measurement points, and the difference between the two groups increased over time.

[0168] This finding is supported by the observation of average daily weight gain (ADG), as a significant difference was found between the BP and CON groups (see [link to article]). Figure 3 ).

[0169] Example 4 In vivo studies in small ruminants (sheep) – the effects of dietary supplementation with Bacillus pumilus on milk quality and yield. To investigate the effects of a routine diet supplemented with Bacillus pumilus (BP) preserved as DSM 34299 on milk yield and quality, ewes were milked twice daily after weaning at 45 days of age. Milk yield was recorded weekly for each sheep over 30 days, and individual milk samples were collected for milk composition analysis using Milkoscan and Bactoscan (Foss Analytics, Hamburg, Germany).

[0170] Overall Conclusion Strain DSM 34299 has the ability to improve animal performance (lamb birth weight, lamb growth, milk yield and quality).

[0171] Preservation and expert solutions The applicant requests that, prior to the patent grant date, only the following deposited microbial samples be provided to experts, subject to the current regulations of the industrial property offices of the contracting parties to the Budapest Treaty.

[0172] Table 9: Depositation in depositary institutions that have obtained international depositary status, in accordance with the Budapest Convention on the International Recognition of the Preservation of Microorganisms for Patent Proceedings: Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures 7B Inhoffenstr., 38124, Braunschweig, Germany.

[0173] .

Claims

1. A Bacillus pumilus strain selected from the group consisting of: a. the strain deposited with the German Collection of Microorganisms and Cell Cultures under accession number DSM 34299, b. the strain deposited with the German Collection of Microorganisms and Cell Cultures under accession number DSM 34300, and c. a variant strain of DSM 34299 or DSM 34300, obtained by using the deposited strain as starting material and retaining or further improving the properties of DSM 34299 or DSM 34300.

2. The Bacillus pumilus strain or variant thereof according to claim 1, wherein the Bacillus pumilus strain has the following properties: a. sensitivity to ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol; and b. inhibitory activity against Escherichia coli, Staphylococcus carnosus and Clostridium perfringens.

3. A composition comprising at least one Bacillus pumilus strain according to claim 1 or 2 and an acceptable excipient and / or carrier.

4. The composition according to claim 3, comprising the Bacillus pumilus strain deposited as DSM 34299.

5. The composition according to claim 3 or 4, comprising the Bacillus pumilus strain deposited as DSM 34300.

6. The composition according to claim 3, comprising the Bacillus pumilus strain deposited as DSM 34300 and the Bacillus pumilus strain deposited as DSM 34299.

7. The composition according to any one of claims 3 to 6, comprising bacteria from one or more of the following genera: Lactobacillus, Lactococcus, Lactosaccharo-carboxydohus, Streptococcus, Bacillus, Pediococcus, Enterococcus, Leuconostoc, Carnobacterium, Propionibacterium, Bifidobacterium, Clostridium and Pediococcus or any combination thereof.

8. The composition according to any one of claims 3 to 7, wherein the one or more Bacillus pumilus strains are present as spores.

9. The composition of any one of claims 3-8, wherein the composition comprises 1.0 x 10 6 CFU / gram to 1.0 x 10 9 CFU / gram of the Bacillus pumilus.

10. The composition according to any one of claims 3 to 9, for use in preventing, reducing or controlling bacterial colonization or infection.

11. The composition according to claim 9, for use in preventing, reducing or controlling bacterial colonization or infection of Clostridium spp., Escherichia coli and / or Staphylococcus carnosus.

12. The composition according to any one of claims 3 to 9, for use in improving animal performance parameters such as weight gain, milk yield increase and / or milk quality increase.

13. An animal feed, animal feed additive or premix comprising the composition of any one of claims 3 to 9, wherein the composition is present in the animal feed, animal feed additive or premix in an amount to provide between 1 x 10 8 and 1 x 10 11 CFU / head / day of the composition in total, wherein the animal feed, animal feed additive or premix further comprises one or more additional components selected from the group consisting of concentrates, vitamins, minerals, enzymes, amino acids and other feed ingredients.

14. A method for preventing, reducing or controlling bacterial colonization or infection, comprising administering to an animal in need thereof an effective amount of a strain according to claim 1 or 2 or a composition according to any one of claims 3 to 9.

15. The method according to claim 14, wherein colonization or infection by Clostridium species, E. coli and / or S. equi is prevented or controlled.

16. The method according to claim 14 or 15, wherein the animal is a monogastric animal, such as poultry and / or swine.

17. The method according to claim 14 or 15, wherein the animal is a ruminant animal, such as a dairy cow, a beef cow, a sheep, a deer or a goat.

18. A method of improving one or more animal performance parameters selected from the group consisting of: a. increased body weight (BW), b. increased birth weight, c. increased average daily gain (ADG), d. reduced coccidiosis lesion score, e. reduced Eimeria acervulina lesion score, f. reduced overall mortality, g. increased milk yield, h. increased milk fat content, and i. increased milk protein content the method comprising feeding an animal a strain according to claim 1 or 2 or a composition according to any one of claims 3 to 9.

19. A kit comprising a composition according to any one of claims 3 to 9 and instructions for use.

Citation Information

Patent Citations

  • Method of favorably modifying poultry intestinal microflora

    WO1994011492A1

  • Antibiotic sensitive bacillus strains having antimicrobial effect against e. coli and clostridium perfringens and having high sporulation capacity

    WO2013153159A1

  • The efficacy and safety of a marine-derived bacillus strain for use as an in-feed probiotic for newly weaned pigs

    WO2015091770A1

  • Compositions and methods of improving the digestibility of animal feed

    WO2016060935A2

  • Bacillus pumilus strain with probiotic activity

    WO2019002476A1